Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Other Operating Expenses: 2022-2025

Historic Other Operating Expenses for Arcutis Biotherapeutics (ARQT) over the last 3 years, with Sep 2025 value amounting to $8.7 million.

  • Arcutis Biotherapeutics' Other Operating Expenses rose 57.82% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.9 million, marking a year-over-year increase of 120.55%. This contributed to the annual value of $19.1 million for FY2024, which is 283.56% up from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' Other Operating Expenses stood at $8.7 million, which was up 15.92% from $7.5 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Other Operating Expenses' 5-year high stood at $8.8 million during Q1 2025, with a 5-year trough of $269,000 in Q3 2022.
  • Over the past 3 years, Arcutis Biotherapeutics' median Other Operating Expenses value was $3.5 million (recorded in 2024), while the average stood at $4.5 million.
  • Data for Arcutis Biotherapeutics' Other Operating Expenses shows a peak YoY skyrocketed of 365.57% (in 2024) over the last 5 years.
  • Arcutis Biotherapeutics' Other Operating Expenses (Quarterly) stood at $485,000 in 2022, then soared by 363.09% to $2.2 million in 2023, then soared by 207.44% to $6.9 million in 2024, then surged by 57.82% to $8.7 million in 2025.
  • Its Other Operating Expenses was $8.7 million in Q3 2025, compared to $7.5 million in Q2 2025 and $8.8 million in Q1 2025.